Recent Advances in Non-viral Vectors Based on Cationic Niosomes for Gene Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (30 October 2021) | Viewed by 3469
Special Issue Editors
2. Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain
3. Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain
Interests: gene therapy; nonviral vectors; drug delivery; 3D bioprinting; nanotechnology
Interests: gene therapy; non-viral vectors; drug delivery; 3D bioprinting; nanotechnology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nowadays, gene therapy is recognized as a realistic medical option to address some devastating diseases. However, its application into the regular routine of medical practice is still hampered mainly by the disposition of safe and effective gene carrier systems. In this sense, the development of nonviral vectors for gene delivery has caught the attention of the research community, due to their safer profile, lower cost, and easier production. In any case, gene delivery efficiency of nonviral vectors needs to be improved in order to beat viral vector counterparts and find a place in the gene therapy market. Among the wide variety of nonviral vectors, niosomes have recently emerged as a tunable and flexible platform to transport different genetic cargoes into target cells under different conditions and applications. This Special Issue serves as an overview of the current status, challenges, and future progress opportunities of niosomes in gene therapy.
Prof. Dr. Gustavo Puras
Dr. Ilia Villate-Beitia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gene therapy
- nonviral vectors
- niosomes
- nanotechnology
- biomaterials
- gene delivery
- non-ionic surfactant
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
